

C Warren Olanow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9588405/publications.pdf>

Version: 2024-02-01

105
papers

23,446
citations

25031

57
h-index

31843

101
g-index

150
all docs

150
docs citations

150
times ranked

19069
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Movement Disorder Societyâ€sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSâ€UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170. | 3.9 | 4,796 |
| 2 | Levodopa and the Progression of Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2498-2508. | 27.0 | 1,649 |
| 3 | Lewy bodyâ€like pathology in long-term embryonic nigral transplants in Parkinson's disease. <i>Nature Medicine</i> , 2008, 14, 504-506. | 30.7 | 1,472 |
| 4 | A doubleâ€blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. <i>Annals of Neurology</i> , 2003, 54, 403-414. | 5.3 | 1,450 |
| 5 | Disease duration and the integrity of the nigrostriatal system in Parkinsonâ€™s disease. <i>Brain</i> , 2013, 136, 2419-2431. | 7.6 | 965 |
| 6 | A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1268-1278. | 27.0 | 830 |
| 7 | Pathophysiology of the basal ganglia in Parkinson's disease. <i>Trends in Neurosciences</i> , 2000, 23, S8-S19. | 8.6 | 702 |
| 8 | The scientific and clinical basis for the treatment of Parkinson disease (2009). <i>Neurology</i> , 2009, 72, S1-136. | 1.1 | 685 |
| 9 | Understanding cell death in parkinson's disease. <i>Annals of Neurology</i> , 1998, 44, S72-84. | 5.3 | 605 |
| 10 | Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 1164-1172. | 10.2 | 589 |
| 11 | Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. <i>Lancet Neurology</i> , The, 2014, 13, 141-149. | 10.2 | 547 |
| 12 | Failure of the ubiquitinâ€proteasome system in Parkinson's disease. <i>Nature Reviews Neuroscience</i> , 2001, 2, 589-594. | 10.2 | 490 |
| 13 | Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. <i>Lancet Neurology</i> , The, 2006, 5, 677-687. | 10.2 | 461 |
| 14 | Targeting Î±-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. <i>Lancet Neurology</i> , The, 2015, 14, 855-866. | 10.2 | 393 |
| 15 | Factors predictive of the development of Levodopaâ€induced dyskinesia and wearingâ€off in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1064-1071. | 3.9 | 374 |
| 16 | Subthalamic nucleusâ€mediated excitotoxicity in parkinson's disease: A target for neuroprotection. <i>Annals of Neurology</i> , 1998, 44, S175-88. | 5.3 | 344 |
| 17 | Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. <i>Lancet</i> , The, 2014, 384, 545-555. | 13.7 | 336 |
| 18 | Levodopa in the treatment of Parkinson's disease: Current controversies. <i>Movement Disorders</i> , 2004, 19, 997-1005. | 3.9 | 331 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDEâ€PD study. <i>Annals of Neurology</i> , 2010, 68, 18-27. | 5.3 | 330 |
| 20 | Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prionâ€Like Disorder?. <i>Movement Disorders</i> , 2013, 28, 31-40. | 3.9 | 320 |
| 21 | Lewy-body formation is an aggresome-related process: a hypothesis. <i>Lancet Neurology</i> , The, 2004, 3, 496-503. | 10.2 | 278 |
| 22 | Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 383-393. | 3.9 | 271 |
| 23 | Is Parkinson's disease a prion disorder?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12571-12572. | 7.1 | 242 |
| 24 | Gene delivery of neurturin to putamen and substantia nigra in <scp>P</scp>arkinson disease: A doubleâ€blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 248-257. | 5.3 | 224 |
| 25 | Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease. <i>Archives of Neurology</i> , 2005, 62, 905-10. | 4.5 | 206 |
| 26 | The pathogenesis of cell death in Parkinson's disease â€“ 2007. <i>Movement Disorders</i> , 2007, 22, S335-S342. | 3.9 | 191 |
| 27 | Ubiquitinâ€proteasome system and Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1806-1823. | 3.9 | 175 |
| 28 | TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , The, 2006, 5, 1013-1020. | 10.2 | 167 |
| 29 | The Scientific Basis for the Current Treatment of Parkinson's Disease. <i>Annual Review of Medicine</i> , 2004, 55, 41-60. | 12.2 | 165 |
| 30 | Waking up to sleep episodes in Parkinson's Disease. <i>Movement Disorders</i> , 2000, 15, 212-215. | 3.9 | 163 |
| 31 | A randomized, doubleâ€blind, placeboâ€controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008, 23, 2194-2201. | 3.9 | 162 |
| 32 | Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study). <i>Clinical Neuropharmacology</i> , 2004, 27, 58-62. | 0.7 | 161 |
| 33 | Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. <i>Brain</i> , 2002, 125, 2058-2066. | 7.6 | 145 |
| 34 | Why have we failed to achieve neuroprotection in Parkinson's disease?. <i>Annals of Neurology</i> , 2008, 64, S101-S110. | 5.3 | 125 |
| 35 | Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinsonâ€™s disease â€“ Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications. <i>European Polymer Journal</i> , 2017, 88, 524-552. | 5.4 | 124 |
| 36 | Therapeutic prospects for Parkinson disease. <i>Annals of Neurology</i> , 2013, 74, 337-347. | 5.3 | 122 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. <i>Lancet Neurology</i> , The, 2014, 13, 767-776. | 10.2 | 120 |
| 38 | Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 382-392. | 2.5 | 117 |
| 39 | Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646. | 3.9 | 114 |
| 40 | Dopamine agonists and neuroprotection in parkinson's disease. <i>Annals of Neurology</i> , 1998, 44, S167-74. | 5.3 | 108 |
| 41 | Fetal Grafting for Parkinson's Disease: Expression of Immune Markers in Two Patients with Functional Fetal Nigral Implants. <i>Cell Transplantation</i> , 1997, 6, 213-219. | 2.5 | 107 |
| 42 | Deprenyl Protects Mesencephalic Dopamine Neurons from Glutamate Receptor-Mediated Toxicity In Vitro. <i>Journal of Neurochemistry</i> , 1997, 68, 33-39. | 3.9 | 89 |
| 43 | Levodopa: A new look at an old friend. <i>Movement Disorders</i> , 2018, 33, 859-866. | 3.9 | 89 |
| 44 | Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video-based analysis. <i>Movement Disorders</i> , 2009, 24, 336-343. | 3.9 | 84 |
| 45 | Tolcapone. <i>Clinical Neuropharmacology</i> , 2007, 30, 287-294. | 0.7 | 83 |
| 46 | Levodopa: Effect on cell death and the natural history of Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 37-44. | 3.9 | 83 |
| 47 | Dopaminergic transplantation for parkinson's disease: Current status and future prospects. <i>Annals of Neurology</i> , 2009, 66, 591-596. | 5.3 | 80 |
| 48 | Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , The, 2020, 19, 135-144. | 10.2 | 80 |
| 49 | Temporal evolution of microglia and α -synuclein accumulation following foetal grafting in Parkinson's disease. <i>Brain</i> , 2019, 142, 1690-1700. | 7.6 | 75 |
| 50 | Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. <i>Annals of Neurology</i> , 2017, 81, 46-57. | 5.3 | 72 |
| 51 | COMT inhibitors in Parkinson's disease. <i>Neurology</i> , 2004, 62, S72-81. | 1.1 | 70 |
| 52 | The significance of defining preclinical or prodromal Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 666-669. | 3.9 | 69 |
| 53 | Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1366-1372. | 3.9 | 67 |
| 54 | Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. <i>Neurology</i> , 2006, 66, S69-79. | 1.1 | 67 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | The causes of parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. <i>Annals of Neurology</i> , 1998, 44, S189-96. | 5.3 | 65 |
| 56 | Desmethylselegiline, a Metabolite of Selegiline [Deprenyl], Protects Mesencephalic Dopamine Neurons from Excitotoxicity In Vitro. <i>Journal of Neurochemistry</i> , 1997, 68, 434-436. | 3.9 | 61 |
| 57 | Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 485-489. | 3.9 | 60 |
| 58 | Can we achieve neuroprotection with currently available anti-parkinsonian interventions?. <i>Neurology</i> , 2009, 72, S59-64. | 1.1 | 57 |
| 59 | Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. <i>Brain</i> , 2020, 143, 960-975. | 7.6 | 56 |
| 60 | Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy. <i>Movement Disorders</i> , 2005, 20, S3-S10. | 3.9 | 55 |
| 61 | Trophic factors for Parkinson's disease: To live or let die. <i>Movement Disorders</i> , 2015, 30, 1715-1724. | 3.9 | 55 |
| 62 | Levodopa/dopamine replacement strategies in Parkinson's disease-Future directions. <i>Movement Disorders</i> , 2008, 23, S613-S622. | 3.9 | 52 |
| 63 | Parkinsonism associated with Sjögren's syndrome: Three cases and a review of the literature. <i>Movement Disorders</i> , 1999, 14, 262-268. | 3.9 | 51 |
| 64 | Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities. <i>Movement Disorders</i> , 2020, 35, 1731-1744. | 3.9 | 47 |
| 65 | Glial Cells Mediate Toxicity in Glutathione-Depleted Mesencephalic Cultures. <i>Journal of Neurochemistry</i> , 2002, 73, 112-119. | 3.9 | 46 |
| 66 | Long-term effects of rasagiline and the natural history of treated Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1489-1496. | 3.9 | 45 |
| 67 | Parkinson's disease, proteins, and prions: Milestones. <i>Movement Disorders</i> , 2011, 26, 1056-1071. | 3.9 | 36 |
| 68 | Do prions cause Parkinson disease?: The evidence accumulates. <i>Annals of Neurology</i> , 2014, 75, 331-333. | 5.3 | 34 |
| 69 | Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 177-186. | 2.8 | 33 |
| 70 | Peripheral alpha-synuclein and Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 963-966. | 3.9 | 32 |
| 71 | The role of dopamine agonists in the treatment of early Parkinson's disease. <i>Neurology</i> , 2002, 58, S33-41. | 1.1 | 32 |
| 72 | Defining disease-modifying therapies for PD: A road map for moving forward. <i>Movement Disorders</i> , 2010, 25, 1774-1779. | 3.9 | 31 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | The Vatican Meeting on Neuroprotection for Parkinson's Disease. <i>Movement Disorders</i> , 2013, 28, 1-2. | 3.9 | 26 |
| 74 | Targeting α -Synuclein as a therapy for Parkinson's disease: The battle begins. <i>Movement Disorders</i> , 2017, 32, 203-207. | 3.9 | 26 |
| 75 | <i>Once-Weekly</i> Subcutaneous Delivery of <i>Polymer-Linked</i> Rotigotine (<i>SER-214</i>) Provides Continuous Plasma Levels in Parkinson's Disease Patients. <i>Movement Disorders</i> , 2020, 35, 1055-1061. | 3.9 | 24 |
| 76 | The delayed-start study in Parkinson disease. <i>Neurology</i> , 2010, 74, 1149-1150. | 1.1 | 21 |
| 77 | Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity. <i>Movement Disorders</i> , 2022, 37, 6-15. | 3.9 | 21 |
| 78 | Subcutaneous Levodopa Infusion for Parkinson's Disease: 1 <i>Year</i> Data from the <i>Open-Label BeyoND</i> Study. <i>Movement Disorders</i> , 2021, 36, 2687-2692. | 3.9 | 20 |
| 79 | Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. <i>Journal of Huntington's Disease</i> , 2020, 9, 371-380. | 1.9 | 17 |
| 80 | Present and future directions in the management of motor complications in patients with advanced PD. <i>Neurology</i> , 2003, 61, S24-33. | 1.1 | 17 |
| 81 | Milestones in movement disorders clinical trials: Advances and landmark studies. <i>Movement Disorders</i> , 2011, 26, 1003-1014. | 3.9 | 16 |
| 82 | <i>On-Demand</i> Therapy for <i>OFF</i> Episodes in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2244-2253. | 3.9 | 16 |
| 83 | Dietary vitamin E and Parkinson's disease: something to chew on. <i>Lancet Neurology</i> , The, 2003, 2, 74. | 10.2 | 15 |
| 84 | Levodopa therapy for Parkinson's disease: Challenges and future prospects. <i>Movement Disorders</i> , 2008, 23, S495-S496. | 3.9 | 14 |
| 85 | A New Approach to the Development of Disease-Modifying Therapies for PD ; Fighting Another Pandemic. <i>Movement Disorders</i> , 2021, 36, 59-63. | 3.9 | 13 |
| 86 | Gene therapy for Parkinson disease—a hope, or a dream?. <i>Nature Reviews Neurology</i> , 2014, 10, 186-187. | 10.1 | 12 |
| 87 | Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study. <i>Movement Disorders</i> , 2019, 34, 425-429. | 3.9 | 11 |
| 88 | Advances in clinical trials for movement disorders. <i>Movement Disorders</i> , 2015, 30, 1580-1587. | 3.9 | 8 |
| 89 | Fetal grafts for Parkinson's disease: Decades in the making. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6332-6334. | 7.1 | 8 |
| 90 | Dose optimization of apomorphine sublingual film for treating <i>OFF</i> episodes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 93, 27-30. | 2.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Reply: Levodopa in the treatment of Parkinson's disease: Current controversies. <i>Movement Disorders</i> , 2005, 20, 643-644. | 3.9 | 7 |
| 92 | Movement disorders: a step in the right direction. <i>Lancet Neurology</i> , The, 2006, 5, 3-5. | 10.2 | 5 |
| 93 | Reply to Montgomery. <i>Annals of Neurology</i> , 2009, 65, 618-619. | 5.3 | 5 |
| 94 | The baton is passed. <i>Movement Disorders</i> , 2010, 25, 1-1. | 3.9 | 5 |
| 95 | Initiating levodopa therapy for Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 430-430. | 3.9 | 5 |
| 96 | Profile of Mahlon DeLong and Alim Benabid, 2014 Lasker-DeBakey Medical Research Awardees. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17693-17695. | 7.1 | 2 |
| 97 | Translating scientific advances into disease-modifying therapies for Parkinson's Disease. <i>Experimental Neurology</i> , 2017, 298, 135-136. | 4.1 | 1 |
| 98 | Adverse event reporting in clinical trials in Parkinson's Disease: Time for change. <i>Movement Disorders</i> , 2018, 33, 1685-1687. | 3.9 | 1 |
| 99 | <i>Movement Disorders</i> Journal: Yesterday, Today, Tomorrow, and Always. <i>Movement Disorders</i> , 2019, 34, 1814-1816. | 3.9 | 1 |
| 100 | The Etiopathogenesis of Parkinson's Disease: Basic Mechanisms of Neurodegeneration. , 2008, , 1-23. | | 0 |
| 101 | The <i>Movement Disorders</i> journal-Then and now. <i>Movement Disorders</i> , 2011, 26, 935-936. | 3.9 | 0 |
| 102 | New Sections for <i>Movement</i> Disorders. <i>Movement Disorders</i> , 2011, 26, 2179-2179. | 3.9 | 0 |
| 103 | The state of the journalâ€™2013. <i>Movement Disorders</i> , 2013, 28, 259-260. | 3.9 | 0 |
| 104 | Eldad Melamed 1942-2015: Ave atque-A memorial. <i>Movement Disorders</i> , 2016, 31, 39-40. | 3.9 | 0 |
| 105 | A Model-Based Approach for Assessing Parkinsonian Gait and Effects of Levodopa and Deep Brain Stimulation. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society</i> , 2006, , . | 0.5 | 0 |